Kitazato

Kitazato EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Kitazato (368A.T) as of Nov 17, 2026 is 5.78 B JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 5.91 B JPY — a change of -2.20% (lower).

EBITDA

5.78 BJPY

YoY

-2.20%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Kitazato is 2025 5.78 B JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Kitazato was 2024 5.91 B JPY. It decreases by -2.20% lower compared to the previous year.

The Kitazato EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2023
5.13 B JPY
Jan 1, 2024
5.91 B JPY
Jan 1, 2025
5.78 B JPY
The Kitazato EBITDA history
YEAREBITDAYoY
5.78 BJPY-2.20%
5.91 BJPY+15.29%
5.13 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kitazato Stock analysis

What does Kitazato do? Kitazato Corp manufactures and sells medical devices, reagents, and related products for infertility treatment, specializing in reproductive engineering technology for artificial insemination, in vitro fertilization, and cell cryopreservation. The company produces consumables such as medical equipment and reagents used in in vitro fertilization and intracytoplasmic sperm injection, including media, cryo devices, medical devices, and micro tools. Kitazato Corp distributes its products globally, serving markets in Japan, Europe, the United States, China, and India, with a focus on research reagents and medical equipment for infertility treatment. The firm also manufactures and sells medical equipment parts, provides genetic testing services, and offers medical equipment for the elderly. Additionally, Kitazato Corp engages in market research, acquisition of local licenses, and contract management of living cells, expanding its reach into regenerative medicine and related fields. These services and products target healthcare providers, fertility clinics, and research institutions worldwide. Kitazato Corp's revenue streams include the sale of consumables, medical devices, and reagents, as well as genetic testing and contract management services. The company's global distribution network supports sales across key regions, with a strong emphasis on infertility treatment solutions and regenerative medicine technologies. Kitazato is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kitazato stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Kitazato is 5.78 B JPY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Kitazato changed from 5.91 B JPY to 5.78 B JPY, representing a -2.20% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Kitazato since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Kitazato historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Kitazato

All Key Metrics — Kitazato